Immunocompromised patients and COVID-19: how do we protect those most at risk?

Click to increase image sizeClick to decrease image size

Declaration of interest

JS reports grants, personal fees, and non-financial support from AbbVie, Gilead Sciences, Janssen-Cilag, GSK/ViiV Healthcare, MSD, Dr. Falk Pharma GmbH, Diasorin, Deutsche Forschungsgemeinschaft (DFG) and the Central Innovation Programme for small and medium-sized enterprises (ZIM) outside the submitted work. CDS reports grants and personal fees from AbbVie, grants, fees, and non-financial support from Gilead Sciences, grants and personal fees from Janssen-Cilag, grants and personal fees from MSD, grants from Cepheid, personal fees from GSK, grants and personal fees from ViiV Healthcare, during the conduct of the study; fees from AstraZeneca, other from Apeiron, grants, personal fees, and non-financial support from BBraun Melsungen, grants and personal fees from BioNtech, personal fees from Eli Lilly, personal fees from Formycon, personal fees from Moderna, personal fees from Molecular partners, personal fees from Novartis, grants and personal fees from Eli Lilly, personal fees from Roche, personal fees from SOBI, personal fees from Shionogi, and personal fees from Pfizer.

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contribution statement

JS, JE, LR, and CDS contributed substantially to the conception and design of the review article and the interpretation of the relevant literature. CDS has revised the review for intellectual content.

Additional information

Funding

This paper was not funded.